New scleroderma registry aims to unlock secrets of rare disease
NCT ID NCT01656447
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry is collecting medical information and biological samples from 300 adults with scleroderma at a single hospital. The goal is to better understand the disease's features, genetics, and progression. While this study does not test any treatment, the data gathered could help scientists develop new therapies in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help researchers uncover the causes of scleroderma and point toward potential treatments for this currently untreatable condition.
- What could go wrong
- This is an observational registry, not a treatment trial. It collects information only and does not test any therapy, so it may not directly lead to a cure or new drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital for Special Surgery
RECRUITINGNew York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a skin patch ease stomach pain in scleroderma?
- Blood thinner may stop autoimmune disease before it starts
- Can online therapy help scleroderma patients manage daily life?
- Pandemic stress hits hard for arthritis patients
- New shot aims to tame rare autoimmune disease
- Could weak legs be making it hard to breathe? new study investigates